Phase 2 Lung Cancer Trial, Recruiting NCT07407933 Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. Condition: Lung Cancer
Back to Lung Cancer

Phase 2 Lung Cancer Trial, Recruiting

NCT07407933
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People who have been diagnosed with extensive-stage small cell lung cancer (ES-SCLC), confirmed through a lab test of tissue or cell samples
  • People whose general health and ability to carry out daily activities meets a specific level, rated as 0 or 1 on a standard medical scale (meaning fully active or able to carry out light work)
  • People whose blood counts and organ function (such as liver and kidneys) meet certain health thresholds

Who may not be able to join:

  • People who have previously received systemic (whole-body) cancer treatment for extensive-stage small cell lung cancer
  • People who have previously received treatment that targets a protein called B7H3, or a type of drug known as a topoisomerase I inhibitor
  • People who have active brain tumours that have spread from the lung cancer, or who have compression of the spinal cord
  • People who have, or have had, a lung condition called interstitial lung disease or pneumonitis (inflammation of the lung tissue)
  • People who have significant heart disease, such as moderate to severe heart failure

Important: Other eligibility requirements not listed here may also apply. Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 86 0512-62858368

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Registry
ClinicalTrials.gov
Start date
31 March 2026
Est. completion
1 November 2028

Where this trial is recruiting

🇧🇪 Belgium 🇮🇹 Italy 🇵🇱 Poland 🇷🇴 Romania 🇪🇸 Spain 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Nature and Frequency with Dose-Limiting Toxicities (DLTs); Adverse Events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov